AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...

Canaccord Genuity analyst John Young CFA has maintained their bullish stance on ANGO stock, giving a Buy rating today.Pick the best stocks and ...

AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...

AngioDynamics (ANGO) announced it received U.S. FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation. Pick the best ...

AngioDynamics currently has a consensus price ... The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue ...

AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67. ...

A federal judge recently approved Philips paying $25 million to monitor and research the affects of its major respiratory devices recall. The monitoring will occur over the next 15 years ...

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Michael Ehlers, M.D., Ph ...